Skip to main content
SpringerLink
Log in

Gerontology Forum

An Update on the Literature

  • From the World Literature
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. Novartis; preregistration in Europe and phase I/II in the US.

  2. Costs (2006 values) were for vaccinations, outpatient visits, antivirals, hospitalisation, postherpetic neuralgia management and lost work productivity. Costs and benefits were discounted at 3% per annum.

  3. This study was supported by GlaxoSmithKline, UK and F. Hoff-mann-La Roche, Switzerland.

  4. This study was supported by Roche Products.

  5. Patients without Parkinson’s disease referred for echocardiography but with no known valvulopathy.

  6. Ceregene; phase I for Parkinson’s disease in the US.

  7. During which patients received rotigotine 2.25 mg/day patches or placebo.

  8. One author was affiliated with Boehringer Ingelheim Pharma GmbH.

References

  • Ebihara T, Ebihara S, Watando A, et al. Effects of menthol on the triggering of the swallowing reflex in elderly patients with dysphagia. Br J Clin Pharmacol 2006 Sep; 62(3): 369–71

    Article  PubMed  CAS  Google Scholar 

Reference

  • Novartis. Pivotal phase III trial results show Novartis cell culture-derived influenza vaccine well tolerated and efficacious [media release]. 2006 Oct 19. Novartis [online]. Available from URL: http://www.novartis.com [Accessed 2006 Oct 28]

Reference

  • Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2005 Sep 5; 145(5): 317–25

    Google Scholar 

Reference

  • Alpharma Inc. Alpharma announces positive results from a phase II safety, efficacy and pharmacokinetic study of its abuse-deterrent, extended-release opioid [media release]. 2006 Sep 28. Alpharma Inc. [online]. Available from URL: http://www.alpharma.com [Accessed 2006 Oct 7]

Reference

  • Sreekumaran Nair K, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006 Oct 19; 355(16): 1647–59

    Article  PubMed  Google Scholar 

Reference

  • Pines A, Sturdee DW, Birkhäuser M, International Menopause Society. WHI and breast cancer: a response to a recent publication from the WHI. Climacteric 2006 Aug; 9(4): 244

    Article  PubMed  Google Scholar 

Reference

  • van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006 Sep; 22(9): 1757–64

    Article  PubMed  Google Scholar 

Reference

  • Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006 Aug; 60(8): 896–905

    Article  PubMed  CAS  Google Scholar 

Reference

  • Franko J, Kish KJ, O’Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma 2006 Jul; 61(1): 107–10

    Article  PubMed  CAS  Google Scholar 

Reference

Reference

  • Dai Q, Borenstein AR, Wu Y, et al. Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med 2006 Sep; 119(9): 751–9

    Article  PubMed  CAS  Google Scholar 

Reference

  • Dupuy D, Lesbre JP, Andréjak M, et al. Valvular heart disease in patients with Parkinson’s disease treated with pergolide. Drug Saf 2006; 29(10): 1005

    Article  Google Scholar 

Reference

  • Ceregene Inc. Ceregene announces promising phase 1 results from gene therapy trial for Parkinson’s disease [media release]. 2006 Oct 10. Ceregene Inc. [online]. Available from URL: http://www.ceregene.com [Accessed 2006 Oct 21]

Reference

  • Deleu D, Jacob P, Chand P, et al. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 2006 Sep 12; 67(5): 897–9

    Article  PubMed  CAS  Google Scholar 

Reference

  • Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006 Aug 31; 355(9): 896–908

    Article  PubMed  CAS  Google Scholar 

Reference

  • Schwarz Pharma. Positive results for rotigotine in restless legs syndrome [media release]. 2006 Oct 9. Schwarz Pharma [online]. Available from URL: http://www.schwarzpharma.com [Accessed 2006 Oct 14]

Reference

  • Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. One-year persistence of improved quality of life during pramipexole therapy of restless legs syndrome [abtract no. P2127]. 10th Congress of the European Federation of Neurological Societies; 2006 Sep 2; Glasgow [online]. Available from URL: http://www.kenes.com/efns2006 [Accessed 2006 Oct 14]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerontology Forum. Drugs Aging 23, 925–931 (2006). https://doi.org/10.2165/00002512-200623110-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200623110-00007

Search

Navigation